Scarica l'app Stockscreener
13.89
2.11%
-0.30
Dopo l'orario di chiusura:
13.89
Xencor Inc Borsa (XNCR) Ultime notizie
IPO Launch: Will Xencor Inc stock reach Wall Street targetsWeekly Trade Summary & Daily Momentum Trading Reports - moha.gov.vn
Will Xencor Inc. stock benefit from upcoming earnings reports2025 Price Targets & Weekly Return Optimization Alerts - ulpravda.ru
How Xencor Inc. stock reacts to Fed rate cuts2025 Top Decliners & High Accuracy Investment Entry Signals - ulpravda.ru
Will Xencor Inc. stock reach Wall Street targetsQuarterly Investment Review & Community Consensus Trade Alerts - ulpravda.ru
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - BioSpace
Xencor expects to have sufficient cash resources to fund research and development programs and operations through 2028 - MarketScreener
Xencor Expects To Have Sufficient Cash Resources To Fund Research And Development Programs And Operations Through 2028 - TradingView — Track All Markets
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs By Investing.com - Investing.com Australia
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Xencor (NASDAQ:XNCR) Trading Down 7.1%Time to Sell? - MarketBeat
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
The Truth About Xencor Inc: Is This Quiet Biotech About To Explode? - AD HOC NEWS
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR) - Seeking Alpha
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Yahoo Finance
Xencor issued US patent for Xtend FC domain - MSN
Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Xencor SVP Desjarlais sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
Xencor SVP Desjarlais sells $1.15 million in shares - Investing.com
With Xencor Stock Sliding, Have You Assessed The Risk? - Trefis
What drives Xencor Inc stock priceMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
Will Xencor Inc. (XE9) stock remain on Wall Street radar2025 Biggest Moves & Entry Point Strategy Guides - Улправда
Why Xencor Inc. stock attracts global investors2025 Institutional Moves & Low Risk High Reward Ideas - Улправда
VP Desjarlais Files To Sell 73,367 Of Xencor Inc [XNCR] - TradingView — Track All Markets
Can Xencor Inc. stock sustain revenue growth2025 Market Overview & Fast Gain Stock Trading Tips - Улправда
Growth Report: Is Xencor Inc. stock ready for breakoutPortfolio Return Report & Free Safe Entry Trade Signal Reports - Улправда
Can Xencor Inc. stock resist market sell offsJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
How supply shortages influence Xencor Inc. (XE9) stockTrade Entry Summary & Free Community Supported Trade Ideas - Улправда
Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga
Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR - MarketBeat
Barclays Maintains Xencor (XNCR) Overweight Recommendation - Nasdaq
Incyte announces EU approval of Xencor-partnered lymphoma therapy - Seeking Alpha
Xencor’s New Study on XmAb657: A Potential Game-Changer for Muscle Diseases - TipRanks
Xencor Earnings Notes - Trefis
Fundamentals Check: Why Xencor Inc XE9 stock signals breakout potential - moha.gov.vn
Free cash flow per share of Xencor, Inc. – GETTEX:XE9 - TradingView — Track All Markets
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - BioSpace
Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent ExtensionWhat's Changed - simplywall.st
248,706 Shares in Xencor, Inc. $XNCR Acquired by Walleye Capital LLC - MarketBeat
Xencor Granted US Patent Extension of Certain Xtend Antibodies, Expects Additional Royalty Revenue - marketscreener.com
Xencor issued U.S. patent for Xtend Fc domain - TipRanks
Xencor extends Ultomiris royalty term to 2028 with new patent - Investing.com
Xencor extends Ultomiris royalty term to 2028 with new patent By Investing.com - Investing.com South Africa
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):